$3.59
0.56% day before yesterday
NYSE, Dec 27, 10:00 pm CET
ISIN
US68218J1034
Symbol
OABI
Sector
Industry

OmniAb Stock price

$3.59
-0.31 7.95% 1M
-0.18 4.77% 6M
-2.58 41.82% YTD
-2.58 41.82% 1Y
-5.20 59.16% 3Y
-5.20 59.16% 5Y
-5.20 59.16% 10Y
NYSE, Closing price Fri, Dec 27 2024
+0.02 0.56%
ISIN
US68218J1034
Symbol
OABI
Sector
Industry

Key metrics

Market capitalization $434.44m
Enterprise Value $398.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 19.54
P/S ratio (TTM) P/S ratio 21.29
P/B ratio (TTM) P/B ratio 1.48
Revenue growth (TTM) Revenue growth -68.45%
Revenue (TTM) Revenue $20.41m
EBIT (operating result TTM) EBIT $-82.21m
Free Cash Flow (TTM) Free Cash Flow $-46.85m
Cash position $59.38m
EPS (TTM) EPS $-0.62
P/E forward negative
P/S forward 16.87
EV/Sales forward 15.49
Short interest 7.00%
Show more

Is OmniAb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

OmniAb Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a OmniAb forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a OmniAb forecast:

Buy
100%

Financial data from OmniAb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
20 20
68% 68%
100%
- Direct Costs 21 21
21% 21%
102%
-0.50 -0.50
101% 101%
-2%
- Selling and Administrative Expenses 4.23 4.23
71% 71%
21%
- Research and Development Expense 57 57
3% 3%
277%
-61 -61
182% 182%
-300%
- Depreciation and Amortization 21 21
21% 21%
102%
EBIT (Operating Income) EBIT -82 -82
110% 110%
-403%
Net Profit -63 -63
112% 112%
-309%

In millions USD.

Don't miss a Thing! We will send you all news about OmniAb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

OmniAb Stock News

Neutral
Business Wire
12 days ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego. In a presentation titled “Building Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds,” Yasmina Abdiche, Ph.D., Vice Preside...
Neutral
Seeking Alpha
about 2 months ago
OmniAb, Inc. (NASDAQ:OABI ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Alex Xenakis - Truist Securities Jacqueline Kisa - TD Cowen Conor McNamara - RBC Capital Markets Operator Good afternoon, and welcome to OmniAb...
Neutral
Business Wire
about 2 months ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. “We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our technology platform and a growing partnership portfolio. Th...
More OmniAb News

Company Profile

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Head office United States
CEO Matthew Foehr
Employees 106
Founded 2015
Website www.omniab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today